The Enterprise Value as of December 2025 (TTM) for Liminatus Pharma, Inc. Class A Common Stock (LIMN) is 26.51M

According to Liminatus Pharma, Inc. Class A Common Stock’s latest financial reports and current stock price. The company's current Enterprise Value is 26.51M. This represents a change of -77.96% compared to the average of 120.27M of the last 4 quarters.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) Historical Enterprise Value (quarterly & annually)

How has LIMN Enterprise Value performed in the past?

The mean historical Enterprise Value of Liminatus Pharma, Inc. Class A Common Stock over the last ten years is 113.16M. The current 26.51M Enterprise Value has changed 2.24% with respect to the historical average. Over the past ten years (40 quarters), LIMN's Enterprise Value was at its highest in in the June 2025 quarter at 259.91M. The Enterprise Value was at its lowest in in the June 2024 quarter at 39.44M.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Liminatus Pharma, Inc. Class A Common Stock Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) Average Enterprise Value

How has LIMN Enterprise Value performed in the past?

The current Enterprise Value of Liminatus Pharma, Inc. Class A Common Stock (LIMN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Liminatus Pharma, Inc. Class A Common Stock (LIMN) Enterprise Value vs. Peers

How is LIMN’s Enterprise Value compared to its peers?

Liminatus Pharma, Inc. Class A Common Stock’s Enterprise Value is less than Alterity Therapeutics Limited (48.31M), greater than NanoViricides, Inc. (-1125689200518.00), less than Generation Bio Co. (71.40M), greater than Mural Oncology plc (-36538249.00), less than Evaxion Biotech A/S (29.95M), less than BioXcel Therapeutics, Inc. (136.96M), greater than Jasper Therapeutics, Inc. (-7125220.00), less than Dyadic International, Inc. (37.50M), greater than SAB Biotherapeutics, Inc. (13.08M), less than MAIA Biotechnology, Inc. (34.29M),

Build a custom stock screener for Liminatus Pharma, Inc. Class A Common Stock (LIMN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Liminatus Pharma, Inc. Class A Common Stock using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Liminatus Pharma, Inc. Class A Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.